Scoring - Plus Drug Coated Balloon in Femoro-Popliteal Lesions - 6 Months Results of the DCB-Trak-Registry
DOI:
https://doi.org/10.12970/2311-052X.2016.04.01.3Keywords:
Ejection fraction, ventriculography, echocardiography, cardiac surgery.Abstract
Background: Recent trials demonstrated favorable results with drug-coated-balloons (DCB) in femoro-popliteal lesions. Additional vessel preparation with a scoring-balloon prior to DCB-angioplasty might reduce rates of flow-limiting dissections and subsequent need for bail-out stenting due to a controlled laceration of the intimal layer. However, clinical data for this combined procedure are lacking.
Methods: In a single center registry, 20 consecutive patients with femoro-popliteal lesions were treated with a scoring-balloon (VascuTrak®) and a DCB subsequently. The primary endpoint was the clinically driven target lesion revascularization (TLR). Secondary endpoints were clinically driven target vessel revascularization (TVR), binary restenosis (PSV>2.4), change in rutherford classification and ABI. Safety endpoints were major cardiovascular events (cardiovascular death, MI, stroke, death) and need for amputation.
Results: The procedure was successful in 17 patients, 1 patient was lost to follow-up. Therefore 16 patients (4 female) were analyzed at the 6 months follow-up visit. There were no clinically driven TLR or TVR after 6 months. Rutherford classification improved from 3.5±0.97 to 0.88±0.72 (p<0.01) after 6 months. ABI increased from 0.85±0.26 to 1.02±0.19 (p=0.01) after the procedure with no further change at 6 months (1.01±0.15, p=0.83). Duplex ultrasound was performed in 9 patients at 6 months, with one binary restenosis (11%). There were neither major cardiovascular events nor amputations at 6 months follow-up.
Conclusions: Vessel preparation with a scoring-balloon prior to DCB-angioplasty in femoro-popliteal lesions is suggested to improve clinical outcome of patients without any safety concerns. Further trials with more patients are needed for validation of the results of our registry.
References
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45(Suppl S): S5-67.
Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011; 4(5): 495-504. http://dx.doi.org/10.1161/CIRCINTERVENTIONS.111.962324
Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 2013; 6(12): 1295-302. http://dx.doi.org/10.1016/j.jcin.2013.07.010
Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN. PACT SFA randomized trial. Circulation 2015; 131(5): 495-502. http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011004
Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol 2015; 66(21): 2329-38. http://dx.doi.org/10.1016/j.jacc.2015.09.063
Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015; 373(2): 145-53. http://dx.doi.org/10.1056/NEJMoa1406235
Cassese S, Byrne RA, Ott I, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv 2012; 5(4): 582-9. http://dx.doi.org/10.1161/CIRCINTERVENTIONS.112.969972
Micari A, Cioppa A, Vadalà G, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv 2012; 5(3): 331-8. http://dx.doi.org/10.1016/j.jcin.2011.11.010
Poncyljusz W, Falkowski A, Safranow K, Rać M, Zawierucha D. Cutting-balloon angioplasty versus balloon angioplasty as treatment for short atherosclerotic lesions in the superficial femoral artery: randomized controlled trial. Cardiovasc Intervent Radiol 2013; 36(6): 1500-7. http://dx.doi.org/10.1007/s00270-013-0603-5
Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45(2): 312-5. http://dx.doi.org/10.1016/j.jacc.2004.11.026
Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010; 3(3): 267-76. http://dx.doi.org/10.1161/CIRCINTERVENTIONS.109.903468
Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358(7): 689-99. http://dx.doi.org/10.1056/NEJMoa0706356
Fanelli F, Cannavale A, Gazzetti M, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014; 37(4): 898-907. http://dx.doi.org/10.1007/s00270-014-0904-3
Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med 2012; 13(4): 219-23. http://dx.doi.org/10.1016/j.carrev.2012.04.007
Zeller T. 12-months results - DEFINITVE AR study in Vascular Interventional Advances Conference; Las Vegas, USA 2014.
Tellez A, Dattilo R, Mustapha JA, et al. Biological effect of orbital atherectomy and adjunctive paclitaxel-coated balloon therapy on vascular healing and drug retention: early experimental insights into the familial hypercholesterolaemic swine model of femoral artery stenosis. EuroIntervention 2014; 10(8): 1002-8. http://dx.doi.org/10.4244/EIJY14M10_03
Kawaguchi K, Kondo T, Shumiya T, et al. Reduction of early elastic recoil by cutting balloon angioplasty as compared to conventional balloon angioplasty. J Invasive Cardiol 2002; 14(9): 515-9.
Tsetis D, Morgan R, Belli AM. Cutting balloons for the treatment of vascular stenoses. Eur Radiol 2006; 16(8): 1675-83. http://dx.doi.org/10.1007/s00330-006-0181-x
Amighi J, Schillinger M, Dick P, et al. De novo superficial femoropopliteal artery lesions: peripheral cutting balloon angioplasty and restenosis rates--randomized controlled trial. Radiology 2008; 247(1): 267-72. http://dx.doi.org/10.1148/radiol.2471070749
Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 2008; 248(1): 297-302. http://dx.doi.org/10.1148/radiol.2481071159
Cotroneo AR, Pascali D, Iezzi R. Cutting balloon versus conventional balloon angioplasty in short femoropopliteal arterial stenoses. J Endovasc Ther 2008; 15(3): 283-91. http://dx.doi.org/10.1583/08-2366.1
Rabbi JF, Kiran RP, Gersten G, Dudrick SJ, Dardik A. Early results with infrainguinal cutting balloon angioplasty limits distal dissection. Ann Vasc Surg 2004; 18(6): 640-3. http://dx.doi.org/10.1007/s10016-004-0103-9
Canaud L, Alric P, Berthet JP, Marty-Ané C, Mercier G, Branchereau P. Infrainguinal cutting balloon angioplasty in de novo arterial lesions. J Vasc Surg 2008; 48(5): 1182-8. http://dx.doi.org/10.1016/j.jvs.2008.06.053
